Mersana Therapeutics Stock Buy Hold or Sell Recommendation
| MRSN Stock | USD 2.28 0.09 4.11% |
Given the investment horizon of 90 days and your conservative attitude towards risk, our recommendation regarding Mersana Therapeutics is 'Strong Sell'. The recommendation algorithm takes into account all of Mersana Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Mersana Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide. In addition, we conduct extensive research on individual companies such as Mersana and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Mersana |
Execute Mersana Therapeutics Buy or Sell Advice
The Mersana recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Mersana Therapeutics. Macroaxis does not own or have any residual interests in Mersana Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Mersana Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Mersana Therapeutics Trading Alerts and Improvement Suggestions
| Mersana Therapeutics is way too risky over 90 days horizon | |
| Mersana Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 36.85 M. Net Loss for the year was (171.67 M) with loss before overhead, payroll, taxes, and interest of (146.8 M). | |
| Mersana Therapeutics currently holds about 225.13 M in cash with (168.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Citigroup Begins Coverage on Mersana Therapeutics |
Mersana Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Mersana analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Mersana analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Mersana Therapeutics Returns Distribution Density
The distribution of Mersana Therapeutics' historical returns is an attempt to chart the uncertainty of Mersana Therapeutics' future price movements. The chart of the probability distribution of Mersana Therapeutics daily returns describes the distribution of returns around its average expected value. We use Mersana Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Mersana Therapeutics returns is essential to provide solid investment advice for Mersana Therapeutics.
| Mean Return | 0.86 | Value At Risk | -9.72 | Potential Upside | 12.03 | Standard Deviation | 6.60 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Mersana Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Mersana Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Mersana Therapeutics, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Mersana Therapeutics back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Schonfeld Strategic Advisors Llc | 2024-09-30 | 2.2 M | Goldman Sachs Group Inc | 2024-09-30 | 2 M | Boxer Capital Llc | 2024-09-30 | 1.8 M | Silverarc Capital Management, Llc | 2024-09-30 | 1.6 M | Deutsche Bank Ag | 2024-06-30 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.4 M | 5am Venture Management, Llc | 2024-09-30 | 1.3 M | Verition Fund Managegment, Llc | 2024-09-30 | 1.3 M | Longwood Capital Partners Llc | 2024-09-30 | 1.2 M | Ecor1 Capital, Llc | 2024-09-30 | 19.4 M | Nextech Invest Ag | 2024-09-30 | 12.1 M |
Mersana Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (26.7M) | 37.5M | (648K) | (152.7M) | 54.3M | 57.0M | |
| Change In Cash | 2.7M | 192.7M | (77.0M) | (49.1M) | 45.7M | 48.0M | |
| Free Cash Flow | (68.3M) | (75.2M) | (140.6M) | (51.6M) | (171.1M) | (162.5M) | |
| Depreciation | 1.2M | 1.0M | 855K | 927K | 1.5M | 1.1M | |
| Other Non Cash Items | 103K | 148K | 723K | (699K) | (1.1M) | (1.0M) | |
| Capital Expenditures | 605K | 473K | 648K | 2.2M | 2.2M | 1.3M | |
| Net Income | (28.2M) | (88.0M) | (170.1M) | (204.2M) | (171.7M) | (163.1M) | |
| End Period Cash Flow | 62.7M | 255.4M | 178.4M | 129.4M | 175.0M | 122.1M | |
| Change To Netincome | 5.0M | 7.3M | 19.1M | 20.8M | 23.9M | 25.1M | |
| Net Borrowings | 5.0M | (313K) | 18.3M | (272K) | (312.8K) | (297.2K) |
Mersana Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Mersana Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Mersana Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Mersana stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.33 | |
β | Beta against Dow Jones | 4.06 | |
σ | Overall volatility | 6.59 | |
Ir | Information ratio | 0.11 |
Mersana Therapeutics Volatility Alert
Mersana Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Mersana Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Mersana Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Mersana Therapeutics Fundamentals Vs Peers
Comparing Mersana Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Mersana Therapeutics' direct or indirect competition across all of the common fundamentals between Mersana Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Mersana Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Mersana Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Mersana Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Mersana Therapeutics to competition |
| Fundamentals | Mersana Therapeutics | Peer Average |
| Return On Equity | -2.13 | -0.31 |
| Return On Asset | -0.26 | -0.14 |
| Profit Margin | (2.14) % | (1.27) % |
| Operating Margin | (0.96) % | (5.51) % |
| Current Valuation | 157.99 M | 16.62 B |
| Shares Outstanding | 123.53 M | 571.82 M |
| Shares Owned By Insiders | 1.25 % | 10.09 % |
| Shares Owned By Institutions | 95.35 % | 39.21 % |
| Number Of Shares Shorted | 9.42 M | 4.71 M |
| Price To Earning | (0.98) X | 28.72 X |
| Price To Book | 268.50 X | 9.51 X |
| Price To Sales | 8.08 X | 11.42 X |
| Revenue | 36.85 M | 9.43 B |
| Gross Profit | (146.8 M) | 27.38 B |
| EBITDA | (166.08 M) | 3.9 B |
| Net Income | (171.67 M) | 570.98 M |
| Cash And Equivalents | 225.13 M | 2.7 B |
| Cash Per Share | 2.32 X | 5.01 X |
| Total Debt | 33.83 M | 5.32 B |
| Debt To Equity | 0.28 % | 48.70 % |
| Current Ratio | 3.32 X | 2.16 X |
| Book Value Per Share | 0.31 X | 1.93 K |
| Cash Flow From Operations | (168.88 M) | 971.22 M |
| Short Ratio | 9.36 X | 4.00 X |
| Earnings Per Share | (0.60) X | 3.12 X |
| Target Price | 6.5 | |
| Number Of Employees | 123 | 18.84 K |
| Beta | 1.48 | -0.15 |
| Market Capitalization | 281.66 M | 19.03 B |
| Total Asset | 226.06 M | 29.47 B |
| Retained Earnings | (826.36 M) | 9.33 B |
| Working Capital | 150.42 M | 1.48 B |
| Current Asset | 71.4 M | 9.34 B |
Note: Acquisition by Mohan Bala of 58333 shares of Mersana Therapeutics subject to Rule 16b-3 [view details]
Mersana Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Mersana . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Mersana Therapeutics Buy or Sell Advice
When is the right time to buy or sell Mersana Therapeutics? Buying financial instruments such as Mersana Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Mersana Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aluminum Thematic Idea Now
Aluminum
Companies involved in production of aluminum. The Aluminum theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aluminum Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Mersana Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Revenue Per Share 0.286 | Quarterly Revenue Growth 0.637 | Return On Assets (0.26) | Return On Equity (2.13) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.